Trial · NCT02616393
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Best Overall Response Rate (ORR) of Subjects With BM | Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first | Subjects with BM only (Cohorts A and C). Subjects with LM (Cohort B) were excluded. | Percentage of participants (%) | NUMBER |
| PRIMARY | Best ORR of Subjects With LM | Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first | Percentage of participants (%) | NUMBER | |
| SECONDARY | Median Progression-free Survival (PFS) | Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first | Weeks | MEDIAN | |
| SECONDARY | Probability of PFS at 12 Weeks and 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only) | 24 weeks (6 months) | Note: Cohort C (BM-IP) did not have a sufficient number of subjects with events to determine the PFS at 12 or 24 weeks. | Probability | NUMBER |
| SECONDARY | Probability of PFS at 24 Weeks--Cohort C (BM-IP Only) | 24 weeks (6 months) | Note: Insufficient data for PFS probability at 12 weeks | Probability | NUMBER |
| SECONDARY | Probability of OS at 12 Weeks and at 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only) | 24 weeks (6 months) | Note: Cohort C did not have a sufficient number of subjects with events to determine the probability of survival at 12 or 24 weeks. | Probability | NUMBER |
| SECONDARY | Median Time to Progression (TTP)--Cohort A (BM), Cohort B (LM), Cohort C (BM-IP) | Until disease progression, death, unacceptable toxicity, or up to 2 years, whichever occurred first | Weeks | MEDIAN | |
| SECONDARY | Probability of TTP at 12 Weeks and 24 Weeks--Non-CNS Cohort A (BM Only) and Cohort B (LM Only) | 24 weeks (6 months) | Note: Cohort C (BM-IP) did not have a sufficient number of subjects with events to determine the probability of TTP at 12 weeks or 24 weeks. | Probability | NUMBER |
| SECONDARY | Probability of TTP at 24 Weeks--CNS | 24 weeks (6 months) | Probability | NUMBER | |
| SECONDARY | Quality of Life (QoL): Mean Change From Baseline in EORTC-QLQ-C30 Questionnaire Scores | Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first | Note: Not all subjects were available for analysis at all visits. | Score on a scale | MEAN |
| SECONDARY | Quality of Life (QoL): Mean Change From Baseline in EORTC-QLQ-BN20 Questionnaire Scores | Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first | Not all subjects were available for all analyses. | Score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02616393/outcomes